Paradigm Biopharmaceuticals (Paradigm, ASX:PAR) is a commercially-focused drug development company.
We believe identifying and transforming underutilised molecules is the most optimal path to addressing an unmet need. We are taking a novel approach to developing effective, safe treatments for targeted clinical indications where there are currently limited options available to patients.
Our immediate commercial focus is the development of injectable pentosan polysulfate sodium (iPPS/PPS, brand name Zilosul®) for the treatment of osteoarthritis (OA). This is a global unmet need and Paradigm has advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease modifying potential.
Paradigm is headquartered in Melbourne, Australia with offices in the EU and US.
Paradigm Pharmaceuticals Ltd (PAR) is a global biopharmaceutical company driven to discover, develop, and deliver pharmaceutical therapies to improve patients’ health and quality of life.
Paradigm is always looking for people and partners who share our vision.
Belief in Transforming Medicine
At Paradigm, we are dedicated to transforming underutilised molecules as a more cost-effective and accessible way of addressing some of the world’s unmet needs.
The reduction in the time, cost and risk associated with the clinical and commercial development pathway to taking new products to market is significant, and offers new avenues of hope for patients.
Paradigm’s primary focus is to develop pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS).
In OA, trials have already advanced into phase 3, and there are a potential 72m eligible candidates in key markets alone (US, EU5, AU, CAN). Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease-modifying potential.
Paradigm’s approach to market is driven by core competencies and significant experience at both board and executive level in clinical and commercial pharmaceutical development and the execution of clinical studies.
Founder & Chairman
Dr Donna Skerrett,
Corporate governance (CG) underpins the way Paradigm conducts business. We are committed to the highest level of governance and strive to foster a culture that values and rewards exemplary ethical standards, personal and corporate integrity and respect for others.
Our Whistle-blower (WB) policy sets out how Paradigm supports its team and partners so that they can safely express their concerns, know who to contact, how to make a report and the protections available to them.
Our business operates in accordance with the below corporate governance document.
At Paradigm we believe we have an obligation — to our employees, our investors, our partners and the environment — to operate our business safely and sustainably. Our management is responsible for enabling employees to contribute to our environmental objectives and to implement our Environment, Health and Safety Policy (EHS) policy.